JBC PeproTech; Our Business is Cytokines!

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M104209200 on July 9, 2001

J. Biol. Chem., Vol. 276, Issue 36, 33711-33720, September 7, 2001
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
276/36/33711    most recent
M104209200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bougeret, C.
Right arrow Articles by Avraham, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bougeret, C.
Right arrow Articles by Avraham, H.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Functional Analysis of Csk and CHK Kinases in Breast Cancer Cells*

Cécile BougeretDagger , Shuxian JiangDagger , Iafa Keydar§, and Hava AvrahamDagger

From the Dagger  Division of Experimental Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02115 and the § Department of Cell Research and Immunology, Tel Aviv University, Ramat Aviv 69978, Israel

In this report, we analyzed the expression and kinase activities of Csk and CHK kinases in normal breast tissues and breast tumors and their involvement in HRG-mediated signaling in breast cancer cells. Csk expression and kinase activity were abundant in normal human breast tissues, breast carcinomas, and breast cancer cell lines, whereas CHK expression was negative in normal breast tissues and low in some breast tumors and in the MCF-7 breast cancer cell line. CHK kinase activity was not detected in human breast carcinoma tissues (12 of 12) or in the MCF-7 breast cancer cell line (due to the low level of CHK protein expression), but was significantly induced upon heregulin (HRG) stimulation. We have previously shown that CHK associates with the ErbB-2/neu receptor upon HRG stimulation via its SH2 domain and that it down-regulates the ErbB-2/neu-activated Src kinases. Our new findings demonstrate that Csk has no effect on ErbB-2/neu-activated Src kinases upon HRG treatment and that its kinase activity is not modulated by HRG. CHK significantly inhibited in vitro cell growth, transformation, and invasion induced upon HRG stimulation. In addition, tumor growth of wt CHK-transfected MCF-7 cells was significantly inhibited in nude mice. Furthermore, CHK down-regulated c-Src and Lyn protein expression and kinase activity, and the entry into mitosis was delayed in the wt CHK-transfected MCF-7 cells upon HRG treatment. These results indicate that CHK, but not Csk, is involved in HRG-mediated signaling pathways, down-regulates ErbB-2/neu-activated Src kinases, and inhibits invasion and transformation of breast cancer cells upon HRG stimulation. These findings strongly suggest that CHK is a novel negative growth regulator of HRG-mediated ErbB-2/neu and Src family kinase signaling pathways in breast cancer cells.


* This work was supported in part by National Institutes of Health Grants CA 76226 and CA 87290 (to H. A.), by U.S. Army Medical Research and Material Command Grants DAMD 17-98-1-8032 and DAMD 17-99-1-9078 (to H. A.), by Experienced Breast Cancer Research Grant 34080057089 (to H. A.), by the Milheim Foundation (to H. A.), and by the Massachusetts Department of Public Health (to H. A.) and (to C. B.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

This paper is dedicated to Charlene Engelhard for her continuing friendship and support for our research program.

This work was done during the term of an established investigatorship from the American Heart Association (to H. A.). To whom correspondence should be addressed: Division of Experimental Medicine, Beth Israel Deaconess Medical Center, Harvard Institutes of Medicine, 4 Blackfan Circle, Boston, MA 02115. Tel.: 617-667-0073; Fax: 617-975-6373; E-mail: havraham@caregroup.harvard.edu.


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Cancer Res.Home page
M. Vidal, S. Warner, R. Read, and R. L. Cagan
Differing Src Signaling Levels Have Distinct Outcomes in Drosophila
Cancer Res., November 1, 2007; 67(21): 10278 - 10285.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
B.-C. Lee, S. Avraham, A. Imamoto, and H. K. Avraham
Identification of the nonreceptor tyrosine kinase MATK/CHK as an essential regulator of immune cells using Matk/CHK-deficient mice
Blood, August 1, 2006; 108(3): 904 - 907.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. Kaminski, R. Zagozdzon, Y. Fu, P. Mroz, W. Fu, S. Seng, S. Avraham, and H. K. Avraham
Role of Src Kinases in Neu-Induced Tumorigenesis: Challenging the Paradigm Using Csk Homologous Kinase Transgenic Mice
Cancer Res., June 1, 2006; 66(11): 5757 - 5762.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. K. Ayrapetov, N. H. Nam, G. Ye, A. Kumar, K. Parang, and G. Sun
Functional Diversity of Csk, Chk, and Src SH2 Domains due to a Single Residue Variation
J. Biol. Chem., July 8, 2005; 280(27): 25780 - 25787.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
B.-C. Lee, T.-H. Lee, R. Zagozdzon, S. Avraham, A. Usheva, and H. K. Avraham
Carboxyl-Terminal Src Kinase Homologous Kinase Negatively Regulates the Chemokine Receptor CXCR4 through YY1 and Impairs CXCR4/CXCL12 (SDF-1{alpha})-Mediated Breast Cancer Cell Migration
Cancer Res., April 1, 2005; 65(7): 2840 - 2845.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y.-P. Chong, T. D. Mulhern, H.-J. Zhu, D. J. Fujita, J. D. Bjorge, J.-P. Tantiongco, N. Sotirellis, D. S. S. Lio, G. Scholz, and H.-C. Cheng
A Novel Non-catalytic Mechanism Employed by the C-terminal Src-homologous Kinase to Inhibit Src-family Kinase Activity
J. Biol. Chem., May 14, 2004; 279(20): 20752 - 20766.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Myoui, R. Nishimura, P. J. Williams, T. Hiraga, D. Tamura, T. Michigami, G. R. Mundy, and T. Yoneda
C-Src Tyrosine Kinase Activity Is Associated with Tumor Colonization in Bone and Lung in an Animal Model of Human Breast Cancer Metastasis
Cancer Res., August 15, 2003; 63(16): 5028 - 5033.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Kim, R. Zagozdzon, A. Meisler, J. D. Baleja, Y. Fu, S. Avraham, and H. Avraham
Csk Homologous Kinase (CHK) and ErbB-2 Interactions Are Directly Coupled with CHK Negative Growth Regulatory Function in Breast Cancer
J. Biol. Chem., September 20, 2002; 277(39): 36465 - 36470.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.